Pharmaceuticals, Biotechnology & Life Sciences

Precigen insider sale: 185k shares sold by director Kindler post‑Rule 144 filing – a routine RSU vesting move, not a sign of distress. Focus on upcoming clinical milestones.

Insider buys Monopar Therapeutics shares at $30 and $14 – deep discounts to $113.94 – while selling for $111‑113, showing a balanced, risk‑managed strategy.

Monopar Therapeutics insider moves reveal a balanced long‑term strategy, combining ADC innovation, pricing tactics, and robust funding to drive oncology success.

Inside Quoin’s latest buy‑the‑dip move: Langer Dennis purchases 34,534 ADSs at $5.15, signaling confidence in the biotech’s orphan‑drug pipeline amid market volatility.

Insider RSU grants reveal CUE Biopharma’s confidence in its oncology pipeline, backing a promising bispecific antibody and JAK‑STAT inhibitor amid FDA Fast‑Track and orphan designations.

Insider selling continues at Relay Therapeutics—Peter Rahmer sells 4,508 shares for $20.03 each, a routine liquidity move that may impact investor sentiment.

Explore how OMEROS insider trades reveal confidence in its drug pipeline and market strategy, offering insights into liquidity, risk management, and future prospects.

SoftBank Vision Fund’s sale of 6 million Relay Therapeutics shares is a routine rebalancing move, not a signal of concern. Stay tuned to insider trades, regulatory milestones, and the company’s protein‑degrading pipeline for the true drivers of futu…

Tempus AI insider sales: CEO Eric Lefkofsky’s Rule 10b5‑1 trades reveal a cautious liquidity strategy amid AI‑oncology growth and market volatility.

Tilray CFO’s insider trades show confidence and tax‑efficient PSU use, hinting at long‑term growth amid volatile cannabis‑beer market.